The China International Import Expo, as an important platform for global trade, provides healthcare companies with valuable opportunities to showcase their achievements and engage in more open and deeper collaboration with partners for broader market opportunities, said business executives.

They made the remarks as the international exchange platform, in its seventh edition this year, has attracted many leading pharmaceutical and medical device companies to participate, launching an increasing number of innovative health technologies, products, and services for the first time in China at the event.

Lundbeck, a global pharmaceutical company solely focusing on neuroscience, joined the CIIE for the first time this year.

"The CIIE, initiated by China and shared globally, is attracting an increasing number of multinational companies due to its significant 'spillover effect.' As a new friend participant, we at Lundbeck have showcased our 70-year dedication to neuroscience, highlighting our transformative treatments for brain diseases and our achievements in China," said Jens Hoeyer, managing director of Lundbeck for the Chinese mainland and Hong Kong.

"We aim to leverage the CIIE platform to accelerate the introduction of our global innovations into China and expand cooperation with local brain health stakeholders. Together, we are making a positive impact on patients with migraine, depression, and other brain diseases, their caregivers and the society, contributing to the 'Healthy China 2030' initiative."

At the ongoing CIIE, Lundbeck has showcased its dedication and innovative progress in the field of neuroscience, as well as the milestones of expansion into neuro-rare and neuro-specialty area, to develop transformative treatments for more patients with brain disorders.

US-based pharmaceutical company Organon aims to leverage this year's CIIE to further explore women's reproductive health innovations, address the evolving needs of Chinese families, and showcase its collaborations with local partners.

"Organon's presence at the CIIE this year is centered around critical health challenges that are impacting societies in a multi-dimensional way. Shifts in population structure affect us all, and our commitment is clear: to advance innovative solutions that support fertility and tackle broader women's and families' health challenges," said Zafer Unluer, president of Organon China.

"Through the CIIE platform, we aim to accelerate global innovations in China and also bring Chinese innovations into the world. We're dedicated to creating solutions that take root and make a lasting difference, for China and beyond."

The company has brought to the expo its full spectrum of reproductive health solutions, which include assisted reproductive solutions, long-acting reversible contraceptives, and product pipelines for conditions such as endometriosis, uterine adhesions, vaginitis, preeclampsia, and menopause.

Incaier, the healthcare arm of Haier Group, has participated in the expo for five consecutive years. This year, more than 50 percent of its products and solutions are showcased for the first time, including over 40 innovative products and solutions, setting a new record for the company.

For instance, the company debuted its "intravascular targeted temperature management system" prototype, which is developed in collaboration with Capital Medical University. This innovation is expected to have a profound impact on the treatment of stroke.

During the expo, Incaier will host more than 10 events, including the release of the results of a district-level medical community informatization project in Shigatse city, Xizang autonomous region, and a forum on the development and clinical application of blood products, to seek for more collaboration opportunities with global partners on innovation.

Dong Yilang contributed to this story.